Join Free

Research and publish the best content.

NeuroImmunology

8.2K views | +1 today

Tags
Current selected tag: '#Glioma'. Clear

# Glioma Actively Personalized VAccine 1

#BioNTec 1

#blood brain barrier 1

#brain tumors 1

#EU Funds 1

#GAPVAC 1

#Glioma 2

#Immatics 1

#immunotherapy 1

#miRNA 1

#neural stem cells 1

#oncovaccine 1

#tumor-related epileptic seizures 1

NeuroImmunology

Curated by Gilbert C FAURE

Your new post is loading...

Scooped by Gilbert C FAURE from Cancer Pathways inhibitors Collection

Scoop.it!

From journal.frontiersin.org - December 15, 2014 10:21 AM

Krishan Maggon 's curator insight, December 15, 2014 4:03 AM

Front. Cell. Neurosci., 12 December 2014 | doi: 10.3389/fncel.2014.00418Gliomas and the vascular fragility of the blood brain barrierLuiz Gustavo Dubois1†, Loraine Campanati2†, Cassia Righy1, Isabella D’Andrea-Meira1, Tania Cristina Leite de Sampaio e Spohr1, Isabel Porto-Carreiro1, Claudia Maria Pereira3, Joana Balça-Silva4, Suzana Assad Kahn1, Marcos F. DosSantos2, Marcela de Almeida Rabello Oliveira5, Adriana Ximenes-da-Silva5, Maria Celeste Lopes4, Eduardo Faveret1, Emerson Leandro Gasparetto1 and Vivaldo Moura-Neto1,2*

Scooped by Gilbert C FAURE from Cancer Immunotherapy Review and Collection

Scoop.it!

EU-Funded Consortium led by immatics and BioNTech to Advance a Novel Class of Fully Personalized Therapeutic Cancer Vaccines into Clinical Trials for Brain Cancer / Treatment News / News / CheckOrphan | NeuroImmunology | Scoop.it

From www.checkorphan.org - November 18, 2014 9:31 AM

Krishan Maggon 's curator insight, October 15, 2014 11:36 AM

GAPVAC was launched in 2013 designed to create, manufacture and develop actively personalized vaccines (APVACs) tailored to the individual characteristics of the patient's tumor and immune system. It is based on combining latest state-of-the-art technologies, including next-generation sequencing (NGS), high-sensitivity mass spectrometry and innovative immunomonitoring approaches to generate an optimal therapy for the individual patient.

The consortium is supported by a €6 million grant from the European Union Framework 7 (EU FP7) program.

Frontiers | Gliomas and the vascular fragility of the blood brain barrier | Frontiers in Cellular Neuroscience

EU-Funded Consortium led by immatics and BioNTech to Advance a Novel Class of Fully Personalized Therapeutic Cancer Vaccines into Clinical Trials for Brain Cancer / Treatment News / News / CheckOrphan